1. ¹Division of Hematology, Istituto Scientifico Policlinico San Matteo, University of Pavia, Pavia, Italy
2. ²Division of Hematology, Ospedale Niguarda, Milano, Italy

Correspondence: Dr A Corso, Division of Hematology, Policlinico San Matteo, Via Golgi 2, 27100 Pavia, Italy. E-mail: a.corso@smatteo.pv.it

Received 23 May 2005; Accepted 29 July 2005; Published online 26 September 2005.

Abstract

From 2000 to 2004, 152 patients with multiple myeloma aged 65 years, enrolled in high-dose programs, were treated with two schedules of DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin): 106 patients (group I) were mobilized with the infusional version of DCEP (infusional-DCEP), and 46 patients (group II) with a shorter version (DCEP-short). The median number of CD34⁺ cells collected was similar in the two groups as was the percentage of patients yielding 4 10⁶ cells/kg. The proportion of patients in whom mobilization failed was similar in the two groups. The incidence of WHO grade III neutropenia was higher in group II, although the difference was not statistically significant; the percentage of patients requiring hospitalization for severe infections was similar in the two groups. The incidence of WHO grade IV thrombocytopenia did not differ between the two groups. The response rate was 72% in group I and 80% in group II with similar percentages of patients achieving good responses. DCEP-short is a good mobilizing regimen, sharing the same characteristics as infusional-DCEP: high mobilizing efficacy, low toxicity and good antitumor activity. This new schedule of DCEP does, however, allow complete outpatient management and so could be advantageously included in any high-dose therapy program.